The Center for Bioanalytic Metrology (CBM) advances U.S. competitiveness by working with industry to solve current, emerging, and industry-relevant challenges in measurement science and technology. The CBM has two overarching objectives: to deliver best-in-class molecular measurement tools and expertise that enable the development of powerful new technologies and capabilities across the pharmaceutical, biotechnology, nutrition and agriculture, energy, and analytical instrumentation sectors; and to serve as a proving ground for applications of new instrumentation to cutting-edge chemical and biochemical problems. Measurement science, and associated instrumentation, is a key contributor to the U.S. economy, enabling advances in everything from drug discovery to materials manufacturing. By bringing together companies in these high-technology sectors with major analytical instrument makers, CBM bridges the gap between the initial demonstration of new ideas — the traditional province of academia — and the delivery of practical technologies.
Research Areas
CBM provides its members with research solutions in a variety of areas, including:
Analysis of rare or extremely dilute cells, molecules, exosomes, etc.
Artificial intelligence-driven instrumentation, feedback optimization, and "driverless" instruments.
Discrimination between large biomolecules and their multimolecule complexes.
Enhanced imaging of cells, organisms, and chemical processes.
Massively parallel approaches to chemical cytometry, genetic profiling, and panel screening.
Online and nearline in situ measurements.
Point-of-use analysis, companion diagnostics, and inexpensive testing in the field.
Reduced volume/materials analysis and experimentation at high throughput and productivity.
Ultrahigh sensitivity assays for trace-level biomarkers and impurities.
Facilities & Resources
Partner Organizations
Abbreviation |
CBM
|
Country |
United States
|
Region |
Americas
|
Primary Language |
English
|
Evidence of Intl Collaboration? |
|
Industry engagement required? |
Associated Funding Agencies |
Contact Name |
Paul Bohn
|
Contact Title |
Center Director
|
Contact E-Mail |
pbohn@nd.edu
|
Website |
|
General E-mail |
|
Phone |
|
Address |
The Center for Bioanalytic Metrology (CBM) advances U.S. competitiveness by working with industry to solve current, emerging, and industry-relevant challenges in measurement science and technology. The CBM has two overarching objectives: to deliver best-in-class molecular measurement tools and expertise that enable the development of powerful new technologies and capabilities across the pharmaceutical, biotechnology, nutrition and agriculture, energy, and analytical instrumentation sectors; and to serve as a proving ground for applications of new instrumentation to cutting-edge chemical and biochemical problems. Measurement science, and associated instrumentation, is a key contributor to the U.S. economy, enabling advances in everything from drug discovery to materials manufacturing. By bringing together companies in these high-technology sectors with major analytical instrument makers, CBM bridges the gap between the initial demonstration of new ideas — the traditional province of academia — and the delivery of practical technologies.
Abbreviation |
CBM
|
Country |
United States
|
Region |
Americas
|
Primary Language |
English
|
Evidence of Intl Collaboration? |
|
Industry engagement required? |
Associated Funding Agencies |
Contact Name |
Paul Bohn
|
Contact Title |
Center Director
|
Contact E-Mail |
pbohn@nd.edu
|
Website |
|
General E-mail |
|
Phone |
|
Address |
Research Areas
CBM provides its members with research solutions in a variety of areas, including:
Analysis of rare or extremely dilute cells, molecules, exosomes, etc.
Artificial intelligence-driven instrumentation, feedback optimization, and "driverless" instruments.
Discrimination between large biomolecules and their multimolecule complexes.
Enhanced imaging of cells, organisms, and chemical processes.
Massively parallel approaches to chemical cytometry, genetic profiling, and panel screening.
Online and nearline in situ measurements.
Point-of-use analysis, companion diagnostics, and inexpensive testing in the field.
Reduced volume/materials analysis and experimentation at high throughput and productivity.
Ultrahigh sensitivity assays for trace-level biomarkers and impurities.